1
|
Luo M, He N, Xu Q, Wen Z, Wang Z, Zhao J, Liu Y. Roles of prostaglandins in immunosuppression. Clin Immunol 2024; 265:110298. [PMID: 38909972 DOI: 10.1016/j.clim.2024.110298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Revised: 06/07/2024] [Accepted: 06/21/2024] [Indexed: 06/25/2024]
Abstract
Prostaglandins (PGs) play a crucial and multifaceted role in various physiological processes such as intercellular signaling, inflammation regulation, neurotransmission, vasodilation, vasoconstriction, and reproductive functions. The diversity and biological significance of these effects are contingent upon the specific types or subtypes of PGs, with each PG playing a crucial role in distinct physiological and pathological processes. Particularly within the immune system, PGs are essential in modulating the function of immune cells and the magnitude and orientation of immune responses. Hence, a comprehensive comprehension of the functions PG signaling pathways in immunosuppressive regulation holds substantial clinical relevance for disease prevention and treatment strategies. The manuscript provides a review of recent developments in PG signaling in immunosuppressive regulation. Furthermore, the potential clinical applications of PGs in immunosuppression are also discussed. While research into the immunosuppressive effects of PGs required further exploration, targeted therapies against their immunosuppressive pathways might open new avenues for disease prevention and treatment.
Collapse
Affiliation(s)
- Minjie Luo
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha 410008, Hunan, China; Sepsis Translational Medicine Key Lab of Hunan Province, Changsha 410008, Hunan, China; National Medicine Functional Experimental Teaching Center, Changsha 410008, Hunan, China
| | - Nina He
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha 410008, Hunan, China; Sepsis Translational Medicine Key Lab of Hunan Province, Changsha 410008, Hunan, China; National Medicine Functional Experimental Teaching Center, Changsha 410008, Hunan, China
| | - Qing Xu
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha 410008, Hunan, China; Sepsis Translational Medicine Key Lab of Hunan Province, Changsha 410008, Hunan, China; National Medicine Functional Experimental Teaching Center, Changsha 410008, Hunan, China
| | - Zhongchi Wen
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha 410008, Hunan, China; Sepsis Translational Medicine Key Lab of Hunan Province, Changsha 410008, Hunan, China; National Medicine Functional Experimental Teaching Center, Changsha 410008, Hunan, China
| | - Ziqin Wang
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha 410008, Hunan, China; Sepsis Translational Medicine Key Lab of Hunan Province, Changsha 410008, Hunan, China; National Medicine Functional Experimental Teaching Center, Changsha 410008, Hunan, China
| | - Jie Zhao
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha 410008, Hunan, China; Sepsis Translational Medicine Key Lab of Hunan Province, Changsha 410008, Hunan, China; National Medicine Functional Experimental Teaching Center, Changsha 410008, Hunan, China.
| | - Ying Liu
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha 410008, Hunan, China; Sepsis Translational Medicine Key Lab of Hunan Province, Changsha 410008, Hunan, China; National Medicine Functional Experimental Teaching Center, Changsha 410008, Hunan, China.
| |
Collapse
|
2
|
Silva JBNF, Calcia TBB, Silva CP, Guilherme RF, Almeida-Souza F, Lemos FS, Calabrese KS, Caruso-Neves C, Neves JS, Benjamim CF. ATRvD1 Attenuates Renal Tubulointerstitial Injury Induced by Albumin Overload in Sepsis-Surviving Mice. Int J Mol Sci 2021; 22:ijms222111634. [PMID: 34769064 PMCID: PMC8583751 DOI: 10.3390/ijms222111634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 10/15/2021] [Accepted: 10/22/2021] [Indexed: 11/16/2022] Open
Abstract
Novel strategies for the prevention and treatment of sepsis-associated acute kidney injury and its long-term outcomes have been required and remain a challenge in critical care medicine. Therapeutic strategies using lipid mediators, such as aspirin-triggered resolvin D1 (ATRvD1), can contribute to the resolution of acute and chronic inflammation. In this study, we examined the potential effect of ATRvD1 on long-term kidney dysfunction after severe sepsis. Fifteen days after cecal ligation and puncture (CLP), sepsis-surviving BALB/c mice were subjected to a tubulointerstitial injury through intraperitoneal injections of bovine serum albumin (BSA) for 7 days, called the subclinical acute kidney injury (subAKI) animal model. ATRvD1 treatment was performed right before BSA injections. On day 22 after CLP, the urinary protein/creatinine ratio (UPC), histologic parameters, fibrosis, cellular infiltration, apoptosis, inflammatory markers levels, and mRNA expression were determined. ATRvD1 treatment mitigated tubulointerstitial injury by reducing proteinuria excretion, the UPC ratio, the glomerular cell number, and extracellular matrix deposition. Pro-fibrotic markers, such as transforming growth factor β (TGFβ), type 3 collagen, and metalloproteinase (MMP)-3 and -9 were reduced after ATRvD1 administration. Post-septic mice treated with ATRvD1 were protected from the recruitment of IBA1+ cells. The interleukin-1β (IL-1β) levels were increased in the subAKI animal model, being attenuated by ATRvD1. Tumor necrosis factor-α (TNF-α), IL-10, and IL-4 mRNA expression were increased in the kidney of BSA-challenged post-septic mice, and it was also reduced after ATRvD1. These results suggest that ATRvD1 protects the kidney against a second insult such as BSA-induced tubulointerstitial injury and fibrosis by suppressing inflammatory and pro-fibrotic mediators in renal dysfunction after sepsis.
Collapse
Affiliation(s)
- José Bruno N. F. Silva
- Institute of Microbiology Paulo de Góes (IMPG), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil; (J.B.N.F.S.); (R.F.G.)
| | - Thayanne B. B. Calcia
- Institute of Biophysics Carlos Chagas Filho (IBCCF), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil; (T.B.B.C.); (C.C.-N.)
| | - Cyntia P. Silva
- Institute of Biomedical Sciences (ICB), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil; (C.P.S.); (F.S.L.); (J.S.N.)
| | - Rafael F. Guilherme
- Institute of Microbiology Paulo de Góes (IMPG), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil; (J.B.N.F.S.); (R.F.G.)
| | - Fernando Almeida-Souza
- Laboratory of Immunomodulation and Protozoology, Oswaldo Cruz Institute (IOC), Fiocruz, Rio de Janeiro 21040-900, Brazil; (F.A.-S.); (K.S.C.)
- Postgraduate in Animal Science, State University of Maranhão, São Luís 65055-310, Brazil
| | - Felipe S. Lemos
- Institute of Biomedical Sciences (ICB), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil; (C.P.S.); (F.S.L.); (J.S.N.)
| | - Kátia S. Calabrese
- Laboratory of Immunomodulation and Protozoology, Oswaldo Cruz Institute (IOC), Fiocruz, Rio de Janeiro 21040-900, Brazil; (F.A.-S.); (K.S.C.)
| | - Celso Caruso-Neves
- Institute of Biophysics Carlos Chagas Filho (IBCCF), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil; (T.B.B.C.); (C.C.-N.)
| | - Josiane S. Neves
- Institute of Biomedical Sciences (ICB), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil; (C.P.S.); (F.S.L.); (J.S.N.)
| | - Claudia F. Benjamim
- Institute of Biophysics Carlos Chagas Filho (IBCCF), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil; (T.B.B.C.); (C.C.-N.)
- Correspondence: or ; Tel.: +55-21-3938-6709
| |
Collapse
|
3
|
MicroRNA-155 Modulates Macrophages' Response to Non-Tuberculous Mycobacteria through COX-2/PGE2 Signaling. Pathogens 2021; 10:pathogens10080920. [PMID: 34451384 PMCID: PMC8398909 DOI: 10.3390/pathogens10080920] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2021] [Revised: 07/01/2021] [Accepted: 07/17/2021] [Indexed: 12/19/2022] Open
Abstract
Non-tuberculous mycobacteria (NTM) have been recognized as a causative agent of various human diseases, including severe infections in immunocompromised patients, such as people living with HIV. The most common species identified is the Mycobacterium avium-intracellulare complex (MAI/MAC), accounting for a majority of infections. Despite abundant information detailing the clinical significance of NTM, little is known about host–pathogen interactions in NTM infection. MicroRNAs (miRs) serve as important post-transcriptional regulators of gene expression. Using a microarray profile, we found that the expression of miR-155 and cyclo-oxygenase 2 (COX-2) is significantly increased in bone-marrow-derived macrophages from mice and human monocyte-derived macrophages from healthy volunteers that are infected with NTM. Antagomir against miR-155 effectively suppressed expression of COX-2 and reduced Prostaglandin E2(PGE2) secretion, suggesting that COX-2/PGE2 expression is dependent on miR-155. Mechanistically, we found that inhibition of NF-κB activity significantly reduced miR-155/COX-2 expression in infected macrophages. Most importantly, blockade of COX-2, E-prostanoid receptors (EP2 and EP4) enhanced killing of MAI in macrophages. These findings provide novel mechanistic insights into the role of miR-155/COX-2/PGE2 signalling and suggest that induction of these pathways enhances survival of mycobacteria in macrophages. Defining host–pathogen interactions can lead to novel immunomodulatory therapies for NTM infections which are difficult to treat.
Collapse
|
4
|
Abstract
Immunosuppression is the most commonly used concept to qualify the immune status of patients with either sterile systemic inflammatory response syndrome (SIRS) or sepsis. In this review we attempt to demonstrate that the concept of immunosuppression is an oversimplification of the complex anti-inflammatory response that occurs in patients dealing with a severe sterile or infectious insult. Particularly, the immune status of leukocytes varies greatly depending on the compartment from where they are derived from. Furthermore, although certain functions of immune cells present in the blood stream or in the hematopoietic organs can be significantly diminished, other functions are either unchanged or even enhanced. This juxtaposition illustrates that there is no global defect. The mechanisms called reprogramming or trained innate immunity are probably aimed at preventing a generalized deleterious inflammatory reaction, and work to maintain the defense mechanisms at their due levels.
Collapse
|
5
|
Jadapalli JK, Halade GV. Unified nexus of macrophages and maresins in cardiac reparative mechanisms. FASEB J 2018; 32:5227-5237. [PMID: 29750575 DOI: 10.1096/fj.201800254r] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Macrophages are immune-sensing "big eater" phagocytic cells responsible for an innate, adaptive, and regenerative response. After myocardial infarction, macrophages predominantly clear the deceased cardiomyocyte apoptotic or necrotic neutrophils to develop a regenerative and reparative program with the activation of the lipoxygenase-mediated maresin (MaR) metabolome at the site of ischemic injury. The specialized proresolving molecule and macrophage mediator in resolving inflammation, MaR-1, produced by human macrophages, has potent defining effects that limit polymorphonuclear neutrophil infiltration, enhance uptake of apoptotic PMNs, regulate inflammation resolution and tissue regeneration, and reduce pain. In addition to proresolving and anti-inflammatory actions, MaR-1 displays potent tissue regenerative effects in stroke and is an antinociceptive. Macrophages actively participate in the biosynthesis of bioactive MaR-2, which exhibits anti-inflammatory, proresolving, and atherosclerotic effects. A new class of macrophage-derived molecules, MaR conjugates in tissue regeneration, is identified that regulates phagocytosis and the repair and regeneration of damaged tissue. The presented review provides a current summary of the effect of MaR in resolution pathophysiology, with relevance to a cardiac repair program.-Jadapalli, J. K., Halade, G. V. Unified nexus of macrophages and maresins in cardiac reparative mechanisms.
Collapse
Affiliation(s)
- Jeevan Kumar Jadapalli
- Division of Cardiovascular Disease, Department of Medicine, The University of Alabama, Birmingham, Alabama, USA
| | - Ganesh V Halade
- Division of Cardiovascular Disease, Department of Medicine, The University of Alabama, Birmingham, Alabama, USA
| |
Collapse
|
6
|
Abstract
Sepsis is caused by a dysregulated host response to infection. Immune responses determine the characteristics of sepsis. The body's protection against infection involves danger signal surveillance and recognition from nonself, effector functions in response to sensing danger signals, homeostatic regulation, and generation of immunologic memory. During sepsis, the immune system is activated by pathogen-associated and host-derived molecular patterns. Detecting these molecular patterns generates multisystem responses. Impaired organ function remote to the site of infection is the unifying feature. The processes by which an appropriate response to a microbial invader change from adaptive to maladaptive and dysregulated remain unclear.
Collapse
|
7
|
Huang XP, Wang Y, Chen L, Sun W, Huang Y, Xu Y, Feng TT, Luo EP, Qin AL, Zhao WF, Gan JH. Elevated serum prostaglandin E2 predicts the risk of infection in hepatitis B virus-related acute-on-chronic liver failure patients. ASIAN PAC J TROP MED 2017; 10:916-920. [PMID: 29080622 DOI: 10.1016/j.apjtm.2017.08.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 07/12/2017] [Accepted: 08/18/2017] [Indexed: 10/18/2022] Open
Abstract
OBJECTIVE To evaluate the serum Prostaglandin E2 (PGE2) level in Acute-on-chronic liver failure (ACLF) and determine its predicative value for infection. METHODS From April 2014 to April 2015, ninety-one patients with hepatitis B virus and ACLF but without infection were enrolled into this prospective study that was carried out at our Hospital. Twenty patients with stable chronic hepatitis B were enrolled from the outpatient department and twenty healthy control subjects without any disease were enrolled from hospital staff. Serum PGE2 levels were determined using ELISA at enrollment. Clinical and laboratory parameters were collected. Receiver operating characteristic (ROC) curves were used to determine optimal cut-off values to predict infection. RESULTS Significantly higher PGE2 levels were found in patients with ACLF in comparison with healthy controls and patients with stable CHB (P < 0.0001). In ACLF patients, PGE2 levels were significantly higher in patients that eventually developed infection than those without this complication (P < 0.0001). ROC analysis showed that serum PGE2 (area under the ROC curve, 0.83) could predict infection in patients with ACLF with sensitivity of 78.4% and specificity of 81.5% using a threshold of 141 pg/mL. CONCLUSIONS Serum PGE2 is associated with the susceptibility to secondary infections for patients with ACLF. Increased PGE2 serum levels may serve as a potential biomarker for developing infections in ACLF patients.
Collapse
Affiliation(s)
- Xiao-Ping Huang
- Department of Infectious Diseases, The First Affiliated Hospital of Suzhou University, Suzhou, China
| | - Yan Wang
- Department of Infectious Diseases, The First Affiliated Hospital of Suzhou University, Suzhou, China
| | - Li Chen
- Department of Infectious Diseases, The First Affiliated Hospital of Suzhou University, Suzhou, China
| | - Wei Sun
- Department of Infectious Diseases, The First Affiliated Hospital of Suzhou University, Suzhou, China
| | - Yan Huang
- Department of Infectious Diseases, The First Affiliated Hospital of Suzhou University, Suzhou, China
| | - Ying Xu
- Department of Infectious Diseases, The First Affiliated Hospital of Suzhou University, Suzhou, China
| | - Ting-Ting Feng
- Department of Infectious Diseases, The First Affiliated Hospital of Suzhou University, Suzhou, China
| | - Er-Ping Luo
- Department of Infectious Diseases, The First Affiliated Hospital of Suzhou University, Suzhou, China
| | - Ai-Lan Qin
- Department of Infectious Diseases, The First Affiliated Hospital of Suzhou University, Suzhou, China
| | - Wei-Feng Zhao
- Department of Infectious Diseases, The First Affiliated Hospital of Suzhou University, Suzhou, China
| | - Jian-He Gan
- Department of Infectious Diseases, The First Affiliated Hospital of Suzhou University, Suzhou, China.
| |
Collapse
|
8
|
Basille D, Plouvier N, Trouve C, Duhaut P, Andrejak C, Jounieaux V. Non-steroidal Anti-inflammatory Drugs may Worsen the Course of Community-Acquired Pneumonia: A Cohort Study. Lung 2016; 195:201-208. [PMID: 28005149 DOI: 10.1007/s00408-016-9973-1] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2016] [Accepted: 12/16/2016] [Indexed: 12/15/2022]
Abstract
PURPOSE Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed or used as self-medication in cases of community-acquired pneumonia (CAP). Nevertheless, the consequences of such medication on the risk of pleuroparenchymal complications are not well known. The aim was to investigate whether exposure to NSAIDs prior to hospital admission among patients suffering from CAP is associated with the development of pleural complications or a lung abscess. METHODS All consecutive non-immunocompromised patients with CAP and admitted to a university hospital were prospectively included (2-year period). The risk of pleuropulmonary complications was analyzed according to previous exposure to NSAIDs. RESULTS Of the 221 included patients, 40 (18.1%) had developed a pleuropulmonary complication. NSAIDs intake prior to admission was reported for 24 patients (10.9%) who were younger (50.6 ± 18.5 vs. 66.5 ± 16.4 years; p = 0.001), had less comorbidities (60 vs. 25.1%; p = 0.001), had a longer duration between the first symptoms of CAP and the start of an antibiotic therapy (6.1 ± 7.6 vs. 2.8 ± 3.8 days; p = 0.001), and who had a higher incidence of pleuropulmonary complications (33.3 vs. 16.2%; p = 0.048). In multivariate analyses, two factors were independently associated with the development of pleuroparenchymal complications: NSAIDs intake [Odds Ratio (OR) = 2.57 [1.02-6.64]; p = 0.049] and alcohol abuse (OR = 2.68 [1.27-5.69]; p = 0.01). CONCLUSIONS Our findings suggest that NSAIDs, often taken by young and healthy patients, may worsen the course of CAP with delayed therapy and a higher rate of pleuropulmonary complications.
Collapse
Affiliation(s)
- Damien Basille
- Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, 80054, France. .,Recif Unit, University Hospital Amiens, Amiens, France.
| | - Nathalie Plouvier
- Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, 80054, France
| | - Charlotte Trouve
- Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, 80054, France
| | - Pierre Duhaut
- Recif Unit, University Hospital Amiens, Amiens, France.,Internal Medicine, University Hospital Amiens, Amiens, France
| | - Claire Andrejak
- Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, 80054, France.,Recif Unit, University Hospital Amiens, Amiens, France
| | - Vincent Jounieaux
- Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, 80054, France
| |
Collapse
|
9
|
Viola JR, Lemnitzer P, Jansen Y, Csaba G, Winter C, Neideck C, Silvestre-Roig C, Dittmar G, Döring Y, Drechsler M, Weber C, Zimmer R, Cenac N, Soehnlein O. Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice. Circ Res 2016; 119:1030-1038. [PMID: 27531933 DOI: 10.1161/circresaha.116.309492] [Citation(s) in RCA: 173] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Accepted: 08/16/2016] [Indexed: 12/20/2022]
Abstract
RATIONALE Atheroprogression is a consequence of nonresolved inflammation, and currently a comprehensive overview of the mechanisms preventing resolution is missing. However, in acute inflammation, resolution is known to be orchestrated by a switch from inflammatory to resolving lipid mediators. Therefore, we hypothesized that lesional lipid mediator imbalance favors atheroprogression. OBJECTIVE To understand the lipid mediator balance during atheroprogression and to establish an interventional strategy based on the delivery of resolving lipid mediators. METHODS AND RESULTS Aortic lipid mediator profiling of aortas from Apoe-/- mice fed a high-fat diet for 4 weeks, 8 weeks, or 4 months revealed an expansion of inflammatory lipid mediators, Leukotriene B4 and Prostaglandin E2, and a concomitant decrease of resolving lipid mediators, Resolvin D2 (RvD2) and Maresin 1 (MaR1), during advanced atherosclerosis. Functionally, aortic Leukotriene B4 and Prostaglandin E2 levels correlated with traits of plaque instability, whereas RvD2 and MaR1 levels correlated with the signs of plaque stability. In a therapeutic context, repetitive RvD2 and MaR1 delivery prevented atheroprogression as characterized by halted expansion of the necrotic core and accumulation of macrophages along with increased fibrous cap thickness and smooth muscle cell numbers. Mechanistically, RvD2 and MaR1 induced a shift in macrophage profile toward a reparative phenotype, which secondarily stimulated collagen synthesis in smooth muscle cells. CONCLUSIONS We present evidence for the imbalance between inflammatory and resolving lipid mediators during atheroprogression. Delivery of RvD2 and MaR1 successfully prevented atheroprogression, suggesting that resolving lipid mediators potentially represent an innovative strategy to resolve arterial inflammation.
Collapse
Affiliation(s)
- Joana R Viola
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Patricia Lemnitzer
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Yvonne Jansen
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Gergely Csaba
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Carla Winter
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Carlos Neideck
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Carlos Silvestre-Roig
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Gunnar Dittmar
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Yvonne Döring
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Maik Drechsler
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Christian Weber
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Ralf Zimmer
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Nicolas Cenac
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.)
| | - Oliver Soehnlein
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
| |
Collapse
|
10
|
Wong JJL, Au AYM, Gao D, Pinello N, Kwok CT, Thoeng A, Lau KA, Gordon JEA, Schmitz U, Feng Y, Nguyen TV, Middleton R, Bailey CG, Holst J, Rasko JEJ, Ritchie W. RBM3 regulates temperature sensitive miR-142-5p and miR-143 (thermomiRs), which target immune genes and control fever. Nucleic Acids Res 2016; 44:2888-97. [PMID: 26825461 PMCID: PMC4824108 DOI: 10.1093/nar/gkw041] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Accepted: 01/13/2016] [Indexed: 12/27/2022] Open
Abstract
Fever is commonly used to diagnose disease and is consistently associated with increased mortality in critically ill patients. However, the molecular controls of elevated body temperature are poorly understood. We discovered that the expression of RNA-binding motif protein 3 (RBM3), known to respond to cold stress and to modulate microRNA (miRNA) expression, was reduced in 30 patients with fever, and in THP-1-derived macrophages maintained at a fever-like temperature (40°C). Notably, RBM3 expression is reduced during fever whether or not infection is demonstrable. Reduced RBM3 expression resulted in increased expression of RBM3-targeted temperature-sensitive miRNAs, we termed thermomiRs. ThermomiRs such as miR-142–5p and miR-143 in turn target endogenous pyrogens including IL-6, IL6ST, TLR2, PGE2 and TNF to complete a negative feedback mechanism, which may be crucial to prevent pathological hyperthermia. Using normal PBMCs that were exogenously exposed to fever-like temperature (40°C), we further demonstrate the trend by which decreased levels of RBM3 were associated with increased levels of miR-142–5p and miR-143 and vice versa over a 24 h time course. Collectively, our results indicate the existence of a negative feedback loop that regulates fever via reduced RBM3 levels and increased expression of miR-142–5p and miR-143.
Collapse
Affiliation(s)
- Justin J-L Wong
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia
| | - Amy Y M Au
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia
| | - Dadi Gao
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia Bioinformatics Laboratory, Centenary Institute, Camperdown 2050, Australia
| | - Natalia Pinello
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia
| | - Chau-To Kwok
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia
| | - Annora Thoeng
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia
| | - Katherine A Lau
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia
| | - Jane E A Gordon
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia
| | - Ulf Schmitz
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia
| | - Yue Feng
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia
| | - Trung V Nguyen
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia
| | - Robert Middleton
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia Bioinformatics Laboratory, Centenary Institute, Camperdown 2050, Australia
| | - Charles G Bailey
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia
| | - Jeff Holst
- Sydney Medical School, University of Sydney, NSW 2006, Australia Origins of Cancer Program, Centenary Institute, Camperdown 2050, Australia
| | - John E J Rasko
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia Cell and Molecular Therapies, Royal Prince Alfred Hospital, Camperdown 2050, Australia
| | - William Ritchie
- Gene & Stem Cell Therapy Program, Centenary Institute, Camperdown 2050, Australia Sydney Medical School, University of Sydney, NSW 2006, Australia Bioinformatics Laboratory, Centenary Institute, Camperdown 2050, Australia CNRS, UMR 5203, Montpellier 34094, France
| |
Collapse
|
11
|
Hong JS, Romero R, Lee DC, Than NG, Yeo L, Chaemsaithong P, Ahn S, Kim JS, Kim CJ, Kim YM. Umbilical cord prostaglandins in term and preterm parturition. J Matern Fetal Neonatal Med 2015; 29:523-31. [PMID: 25758616 DOI: 10.3109/14767058.2015.1011120] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVE Prostaglandins (PGs) are considered the universal mediators of parturition. Amniotic fluid PGE2 and PGF2α concentrations increase before the onset of spontaneous labor at term, as well as during labor. This study was conducted to determine if the concentrations of umbilical cord PGE2 and PGF2α change with advancing gestational age, spontaneous labor at term, and preterm labor (with and without funisitis). METHODS Umbilical cord (UC) tissue samples were obtained from women (N = 158) with singleton pregnancies in the following groups: (1) term deliveries without labor (TNL; n = 20); (2) term deliveries with labor (TIL; n = 20); (3) spontaneous preterm deliveries (sPTD) with (n = 20) and without acute funisitis (n = 20); and (4) preeclampsia without labor (n = 78). The concentrations of PGs were determined in different locations of the UC. PGE2 and PGF2α were measured by specific immunoassays. Non-parametric statistics were used for analysis. RESULTS (1) In spontaneous preterm deliveries, the median UC PGE2 concentration was higher in cases with funisitis than in those without funisitis (233.7 pg/µg versus 87.4 pg/µg of total protein, p = 0.001); (2) the median UC PGE2 concentration in sPTD with funisitis was also higher than that obtained from samples who had undergone labor at term (233.7 pg/µg versus 116.1 pg/µg of total protein, p = 0.03); (3) the UC PGE2 and PGF2α concentration increased as a function of advancing gestational age before 36 weeks (PGE2: ρ = 0.59, p < 0.001; PGF2α: ρ = 0.39, p = 0.01), but not after 36 weeks (PGE2: ρ = -0.1, p = 0.5; PGF2α: ρ = -0.2, p = 0.2); (4) the median UC concentrations of PGE2 and PGF2α at term was similar in samples obtained from women with and without labor (PGE2: TNL 133.7 pg/µg versus TIL 116.1 pg/µg of total protein, p = 0.9; PGF2α: TNL 8.4 pg/µg versus TIL 8.1 pg/µg of total protein, p = 0.7); and (5) there was no correlation between UC PG concentration and gestational age at term pregnancy (PGE2: ρ = 0.01, p = 0.9; PGF2α: ρ = 0.07, p = 0.7). CONCLUSIONS (1) PGE2 concentrations in the UC are higher in the presence of acute funisitis than in the absence of this lesion; (2) spontaneous labor at term was not associated with a change in the UC concentration of PGE2 and PGF2α; and (3) the UC concentrations of PGE2 and PGF2α increased as a function of gestational age. We propose that UC PGs act as inflammatory mediators generated in the context of fetal systemic inflammation.
Collapse
Affiliation(s)
- Joon-Seok Hong
- a Perinatology Research Branch, NICHD/NIH/DHHS , Bethesda, MD, and Detroit , MI , USA .,b Department of Obstetrics and Gynecology , Seoul National University Bundang Hospital , Gyeonggi-do , Republic of Korea
| | - Roberto Romero
- a Perinatology Research Branch, NICHD/NIH/DHHS , Bethesda, MD, and Detroit , MI , USA .,c Department of Obstetrics and Gynecology , University of Michigan , Ann Arbor , MI , USA .,d Department of Epidemiology and Biostatistics , Michigan State University , East Lansing , MI , USA
| | - Deug-Chan Lee
- a Perinatology Research Branch, NICHD/NIH/DHHS , Bethesda, MD, and Detroit , MI , USA .,e College of Biomedical Science, Kangwon National University , Chuncheon , Republic of Korea
| | - Nandor Gabor Than
- a Perinatology Research Branch, NICHD/NIH/DHHS , Bethesda, MD, and Detroit , MI , USA .,f Department of Obstetrics and Gynecology , Wayne State University School of Medicine , Detroit , MI , USA
| | - Lami Yeo
- a Perinatology Research Branch, NICHD/NIH/DHHS , Bethesda, MD, and Detroit , MI , USA .,f Department of Obstetrics and Gynecology , Wayne State University School of Medicine , Detroit , MI , USA
| | - Piya Chaemsaithong
- a Perinatology Research Branch, NICHD/NIH/DHHS , Bethesda, MD, and Detroit , MI , USA .,f Department of Obstetrics and Gynecology , Wayne State University School of Medicine , Detroit , MI , USA
| | - Soyeon Ahn
- g Medical Research Collaborating Center, Seoul National University Bundang Hospital , Gyeonggi-do , Republic of Korea
| | - Jung-Sun Kim
- h Department of Pathology , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of Korea
| | - Chong Jai Kim
- a Perinatology Research Branch, NICHD/NIH/DHHS , Bethesda, MD, and Detroit , MI , USA .,i Department of Pathology , Asan Medical, Center University of Ulsan College of Medicine , Seoul , Republic of Korea , and
| | - Yeon Mee Kim
- a Perinatology Research Branch, NICHD/NIH/DHHS , Bethesda, MD, and Detroit , MI , USA .,j Department of Pathology , Haeundae Paik Hospital, Inje University College of Medicine , Busan , Republic of Korea
| |
Collapse
|
12
|
Bellner L, Marrazzo G, van Rooijen N, Dunn MW, Abraham NG, Schwartzman ML. Heme oxygenase-2 deletion impairs macrophage function: implication in wound healing. FASEB J 2014; 29:105-15. [PMID: 25342128 DOI: 10.1096/fj.14-256503] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Heme oxygenase (HO)-2 deficiency impairs wound healing and exacerbates inflammation following injury. We examine the impact of HO-2 deficiency on macrophage function and the contribution of macrophage HO-2 to inflammatory and repair responses to injury. Corneal epithelial debridement was performed in control and macrophage-depleted HO-2(-/-) and wild-type (WT) mice and in bone marrow chimeras. Peritoneal macrophages were collected for determination of phagocytic activity and classically activated macrophage (M1)-alternatively activated macrophage (M2) polarization. Depletion of macrophages delayed corneal healing (13.2%) and increased neutrophil infiltration (54.1%) by day 4 in WT mice, whereas in HO-2(-/-) mice, it did not worsen the already impaired wound healing and exacerbated inflammation. HO-2(-/-) macrophages displayed an altered M1 phenotype with no significant expression of M2 or M2-like activated cells and a 31.3% reduction in phagocytic capacity that was restored by inducing HO-1 activity or supplementing biliverdin. Macrophage depletion had no effect, whereas adoptive transfer of WT bone marrow improved wound healing (34% on day 4) but did not resolve the exaggerated inflammatory response in HO-2(-/-) mice. These findings indicate that HO-2-deficient macrophages are dysfunctional and that macrophage HO-2 is required for proper macrophage function but is insufficient to correct the impaired healing of the HO-2(-/-) cornea, suggesting that corneal epithelial expression of HO-2 is a key to resolution and repair in wound healing.
Collapse
Affiliation(s)
| | | | - Nico van Rooijen
- Department of Molecular Cell Biology, Faculty of Medicine, Vrije Universiteit, Amsterdam, The Netherlands
| | | | - Nader G Abraham
- Department of Pharmacology, Department of Medicine, New York Medical College, Valhalla, New York, USA; and
| | | |
Collapse
|
13
|
Degraaf AJ, Zasłona Z, Bourdonnay E, Peters-Golden M. Prostaglandin E2 reduces Toll-like receptor 4 expression in alveolar macrophages by inhibition of translation. Am J Respir Cell Mol Biol 2014; 51:242-50. [PMID: 24601788 DOI: 10.1165/rcmb.2013-0495oc] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Alveolar macrophages (AMs) represent the first line of innate immune defense in the lung. AMs use pattern recognition receptors (PRRs) to sense pathogens. The best studied PRR is Toll-like receptor (TLR)4, which detects LPS from gram-negative bacteria. The lipid mediator prostaglandin (PG)E2 dampens AM immune responses by inhibiting the signaling events downstream of PRRs. We examined the effect of PGE2 on TLR4 expression in rat AMs. Although PGE2 did not reduce the mRNA levels of TLR4, it decreased TLR4 protein levels. The translation inhibitor cycloheximide reduced TLR4 protein levels with similar kinetics as PGE2, and its effects were not additive with those of the prostanoid, suggesting that PGE2 inhibits TLR at the translational level. The action of PGE2 could be mimicked by the direct stimulator of cAMP formation, forskolin, and involved E prostanoid receptor 2 ligation and cAMP-dependent activation of unanchored type I protein kinase A. Cells pretreated with PGE2 for 24 hours exhibited decreased TNF-α mRNA and protein levels in response to LPS stimulation. Knockdown of TLR4 protein by small interfering RNA to the levels achieved by PGE2 treatment likewise decreased TNF-α mRNA and protein in response to LPS, establishing the functional significance of this PGE2 effect. We provide the first evidence of a lipid mediator acting through its cognate G protein-coupled receptor to affect PRR translation. Because PGE2 is produced in abundance at sites of infection, its inhibitory effects on AM TLR4 expression have important implications for host defense in the lung.
Collapse
Affiliation(s)
- Angela Juliette Degraaf
- Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, Michigan
| | | | | | | |
Collapse
|
14
|
Fullerton JN, O'Brien AJ, Gilroy DW. Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol 2013; 35:12-21. [PMID: 24268519 PMCID: PMC3884129 DOI: 10.1016/j.it.2013.10.008] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2013] [Revised: 09/16/2013] [Accepted: 10/22/2013] [Indexed: 12/21/2022]
Abstract
Aberrant LM levels contribute to immune dysfunction in CI. Aberrance reflects dysregulation of inflammatory resolution pathways or their failure. Targeted manipulation of LMs restores immune competence and outcomes in animal models. Stratified resolution-based immunomodulatory strategies hold therapeutic potential.
Sepsis, trauma, burns, and major surgical procedures activate common systemic inflammatory pathways. Nosocomial infection, organ failure, and mortality in this patient population are associated with a quantitatively different reprioritization of the circulating leukocyte transcriptome to the initial inflammatory insult, greater in both magnitude and duration, and secondary to multiple observed defects in innate and adaptive immune function. Dysregulation of inflammatory resolution processes and associated bioactive lipid mediators (LMs) mechanistically contribute to this phenotype. Recent data indicate the potential efficacy of therapeutic interventions that either reduce immunosuppressive prostaglandins (PGs) or increase specialized proresolving LMs. Here, we reassess the potential for pharmacological manipulation of these LMs as therapeutic approaches for the treatment of critical illness (CI).
Collapse
Affiliation(s)
- James N Fullerton
- Centre for Clinical Pharmacology, Division of Medicine, Rayne Institute, 5 University Street, University College London, London, WC1E 6JF, UK.
| | - Alastair J O'Brien
- Centre for Clinical Pharmacology, Division of Medicine, Rayne Institute, 5 University Street, University College London, London, WC1E 6JF, UK
| | - Derek W Gilroy
- Centre for Clinical Pharmacology, Division of Medicine, Rayne Institute, 5 University Street, University College London, London, WC1E 6JF, UK
| |
Collapse
|
15
|
The Cinderella Effect: Searching for the Best Fit between Mouse Models and Human Diseases. J Invest Dermatol 2013; 133:2509-2513. [DOI: 10.1038/jid.2013.238] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2013] [Revised: 04/12/2013] [Accepted: 04/27/2013] [Indexed: 01/09/2023]
|
16
|
Rodríguez M, Domingo E, Municio C, Alvarez Y, Hugo E, Fernández N, Sánchez Crespo M. Polarization of the innate immune response by prostaglandin E2: a puzzle of receptors and signals. Mol Pharmacol 2013; 85:187-97. [PMID: 24170779 DOI: 10.1124/mol.113.089573] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Eicosanoids tailor the innate immune response by supporting local inflammation and exhibiting immunomodulatory properties. Prostaglandin (PG) E2 is the most abundant eicosanoid in the inflammatory milieu due to the robust production elicited by pathogen-associated molecular patterns on cells of the innate immune system. The different functions and cell distribution of E prostanoid receptors explain the difficulty encountered thus far to delineate the actual role of PGE2 in the immune response. The biosynthesis of eicosanoids includes as the first step the Ca(2+)- and kinase-dependent activation of the cytosolic phospholipase A2, which releases arachidonic acid from membrane phospholipids, and later events depending on the transcriptional regulation of the enzymes of the cyclooxygenase routes, where PGE2 is the most relevant product. Acting in an autocrine/paracrine manner in macrophages, PGE2 induces a regulatory phenotype including the expression of interleukin (IL)-10, sphingosine kinase 1, and the tumor necrosis factor family molecule LIGHT. PGE2 also stabilizes the suppressive function of myeloid-derived suppressor cells, inhibits the release of IL-12 p70 by macrophages and dendritic cells, and may enhance the production of IL-23. PGE2 is a central component of the inflammasome-dependent induction of the eicosanoid storm that leads to massive loss of intravascular fluid, increases the mortality rate associated with coinfection by Candida ssp. and bacteria, and inhibits fungal phagocytosis. These effects have important consequences for the outcome of infections and the polarization of the immune response into the T helper cell types 2 and 17 and can be a clue to develop pharmacological tools to address infectious, autoimmune, and autoinflammatory diseases.
Collapse
Affiliation(s)
- Mario Rodríguez
- Department of Biochemistry and Molecular Biology, University of Valladolid, Valladolid, Spain (M.R., N.F.); and Institute of Biology and Molecular Genetics, Spanish National Research Council, Valladolid, Spain (E.D., C.M., Y.A., E.H., M.S.C.)
| | | | | | | | | | | | | |
Collapse
|
17
|
Fullerton JN, O'Brien AJ, Gilroy DW. Pathways mediating resolution of inflammation: when enough is too much. J Pathol 2013; 231:8-20. [PMID: 23794437 DOI: 10.1002/path.4232] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2013] [Revised: 06/11/2013] [Accepted: 06/17/2013] [Indexed: 01/22/2023]
Abstract
Patients with critical illness, and in particular sepsis, are now recognized to undergo unifying, pathogenic disturbances of immune function. Whilst scientific and therapeutic focus has traditionally been on understanding and modulating the initial pro-inflammatory limb, recent years have witnessed a refocusing on the development and importance of immunosuppressive 'anti-inflammatory' pathways. Several mechanisms are known to drive this phenomenon; however, no overriding conceptual framework justifies them. In this article we review the contribution of pro-resolution pathways to this phenotype, describing the observed immune alterations in terms of either a failure of resolution of inflammation or the persistence of pro-resolution processes causing inappropriate 'injurious resolution'-a novel hypothesis. The dysregulation of key processes in critical illness, including apoptosis of infiltrating neutrophils and their efferocytosis by macrophages, are discussed, along with the emerging role of specialized cell subtypes Gr1(+) CD11b(+) myeloid-derived suppressor cells and CD4(+) CD25(+) FoxP3(+) T-regulatory cells.
Collapse
Affiliation(s)
- James N Fullerton
- Centre for Clinical Pharmacology, Division of Medicine, University College London, London, UK.
| | | | | |
Collapse
|
18
|
Yuan Z, Panchal D, Syed MA, Mehta H, Joo M, Hadid W, Sadikot RT. Induction of cyclooxygenase-2 signaling by Stomatococcus mucilaginosus highlights the pathogenic potential of an oral commensal. THE JOURNAL OF IMMUNOLOGY 2013; 191:3810-7. [PMID: 24018272 DOI: 10.4049/jimmunol.1300883] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Stomatococcus mucilaginosus is an oral commensal that has been occasionally reported to cause severe infections in immunocompromised patients. There is no information about the pathogenic role of S. mucilaginosus in airway infections. In a cohort of 182 subjects with bronchiectasis, we found that 9% were colonized with S. mucilaginosus in their lower airways by culture growth from bronchoalveolar lavage. To address the pathogenic potential of S.mucilaginosus, we developed a murine model of S. mucilaginosus lung infection. Intratracheal injection of S. mucilaginosus in C57BL/6 mice resulted in a neutrophilic influx with production of proinflammatory cytokines, chemokines, and lipid mediators, mainly PGE₂ with induction of cyclooxygenase-2 (COX-2) in the lungs. Presence of TLR2 was necessary for induction of COX-2 and production of PGE₂ by S. mucilaginosus. TLR2-deficient mice showed an enhanced clearance of S. mucilaginosus compared with wild-type mice. Administration of PGE₂ to TLR2(-/-) mice resulted in impaired clearance of S. mucilaginosus, suggesting a key role for COX-2-induced PGE₂ production in immune response to S. mucilaginosus. Mechanistically, induction of COX-2 in macrophages was dependent on the p38-ERK/MAPK signaling pathway. Furthermore, mice treated with S. mucilaginosus and Pseudomonas aeruginosa showed an increased mortality compared with mice treated with PA103 or S. mucilaginosus alone. Inhibition of COX-2 significantly improved survival in mice infected with PA103 and S. mucilaginosus. These data provide novel insights into the bacteriology and personalized microbiome in patients with bronchiectasis and suggest a pathogenic role for S. mucilaginosus in patients with bronchiectasis.
Collapse
Affiliation(s)
- Zhihong Yuan
- Veterans Affairs Medical Center, Gainesville, FL 32610
| | | | | | | | | | | | | |
Collapse
|
19
|
What's new in Shock? December 2012. Shock 2012; 38:575-6. [PMID: 23160519 DOI: 10.1097/shk.0b013e318278ae5f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|